MYBL2 drives prostate cancer plasticity and identifies CDK2 as a therapeutic vulnerability in RB1-loss and neuroendocrine prostate cancerBeatriz Germán, Leigh Ellis|bioRxiv (Cold Spring Harbor Laboratory)|2024Cited by 2